What is AOD 9604?
AOD 9604 (Anti Obesity Drug 9604) is a synthetic peptide fragment corresponding to amino acids 176 to 191 of human growth hormone, with an additional tyrosine residue at the N terminus. It was developed at Monash University in Melbourne, Australia, making it one of the few research peptides with Australian origins.
The GH Fragment Concept
Human growth hormone has diverse biological effects, including growth promotion, metabolic regulation, and lipolysis (fat breakdown). Research identified that the lipolytic activity of GH resides primarily in the C terminal region (amino acids 176 to 191). AOD 9604 was designed to isolate this metabolic activity without the growth promoting or diabetogenic effects of full length GH.
Mechanism of Action
AOD 9604 stimulates lipolysis through a mechanism similar to natural growth hormone but without affecting IGF 1 levels or insulin sensitivity. Research suggests it enhances fat oxidation, inhibits lipogenesis (new fat formation), and does not affect blood glucose or growth parameters.
Australian Research Heritage
AOD 9604 has a notable regulatory history in Australia. The TGA (Therapeutic Goods Administration) has classified it as a food substance in certain formulations, reflecting its safety profile. This Australian connection makes it particularly relevant for the domestic research community.
Research Applications
Studies have explored AOD 9604 in several contexts including adipose tissue metabolism and lipolysis, cartilage repair and osteoarthritis, metabolic syndrome research, and body composition studies.
Conclusion
AOD 9604 offers researchers a unique tool for studying the metabolic effects of growth hormone signalling in isolation from its growth promoting activities. Its Australian research heritage and established safety profile make it a valuable addition to any metabolic research programme.
All products are for research purposes only. Not for human consumption.